Intermountain is a study site for a new trial by Regeneron Pharmaceuticals that aims to treat and prevent COVID-19 using monoclonal antibodies. According to a news release, the trial commonly known as Anti-SPIKE tests a cocktail of antibodies called REGN-COV. The the Intermountain people receiving this treatment are patients hospitalized with COVID-19.

To create REGN-COV2, Regeneron scientists evaluated fully human antibodies produced from the company’s proprietary VelocImmune® mice, which have been genetically modified to have a human immune system, as well as antibodies isolated from humans who have recovered from COVID-19. They then selected the two most potent, non-competitive and virus-neutralizing antibodies for the program. The antibodies bind to a site of the virus called the spike, neutralizing the virus so that it cannot attach itself to—and make its way inside—healthy cells. Regeneron has a history of creating successful antibody therapies including an Ebola treatment that looks to be approved this fall. Read more about the trial in a CNN report.